07:00 , Jun 8, 2015 |  BC Week In Review  |  Clinical News

Talion bepotastine besilate regulatory update

Mitsubishi Tanabe and Ube said Japan approved an expanded label for allergy drug Talion bepotastine besilate tablets and orally disintegrating tablets to include pediatric patients ages >=7. The selective histamine H1 receptor (HRH1) antagonist...
07:00 , Jun 3, 2013 |  BC Week In Review  |  Company News

Bausch + Lomb ophthalmic news

Bausch + Lomb said that its ISTA Pharmaceuticals Inc. subsidiary will pay about $34 million in civil and criminal fines to the U.S. government to settle litigation involving conduct by ISTA that occurred between January...
07:00 , May 14, 2012 |  BC Week In Review  |  Clinical News

Beposone: Phase II data

Top-line data from a double-blind, U.S. Phase II trial in about 600 patients aged 12 and older with allergic rhinitis due to Mountain Cedar pollen showed that twice-daily Beposone nasal spray significantly reduced total nasal...
07:00 , Apr 2, 2012 |  BC Week In Review  |  Company News

Bausch + Lomb, Ista deal

Bausch + Lomb will acquire fellow ophthalmic company Ista for $9.10 per share in cash, or about $500 million. The price is a 9% premium to Ista's close of $8.38 on March 26, before the...
00:43 , Mar 27, 2012 |  BC Extra  |  Top Story

Bausch + Lomb to acquire Ista for $500M

Bausch + Lomb Inc. (Rochester, N.Y.) will acquire fellow ophthalmic company Ista Pharmaceuticals Inc. (NASDAQ:ISTA) for $9.10 per share, or about $500 million. The price is a 9% premium to Ista's close of $8.38 on...
08:00 , Feb 6, 2012 |  BC Week In Review  |  Clinical News

Beposone: Completed Phase II enrollment

Ista completed enrollment of more than 600 patients with allergic rhinitis due to Mountain Cedar pollen in a U.S. Phase II trial comparing twice-daily beposone nasal spray vs. a nasal spray of each of beposone's...
08:00 , Jan 23, 2012 |  BC Week In Review  |  Company News

Ista, Valeant Pharmaceuticals deal

Valeant increased its unsolicited offer to acquire ophthalmic company Ista to $7.50 per share from $6.50. The new price is a 93% premium to Ista's close of $3.89 on Dec. 15, 2011, the day before...
08:00 , Jan 9, 2012 |  BC Week In Review  |  Clinical News

Beposone: Phase II started

Ista began a U.S. Phase II trial to compare twice-daily beposone nasal spray vs. a nasal spray of each of beposone's components (bepotastine besilate and steroid) alone or placebo for 2 weeks in about 600...
08:00 , Dec 19, 2011 |  BC Week In Review  |  Company News

Ista, Valeant Pharmaceuticals deal

Valeant made public an unsolicited offer to acquire ophthalmic company Ista for $6.50 per share in cash, or about $327 million including $13 million in Ista debt. The price is a 67% premium to Ista's...
01:19 , Dec 17, 2011 |  BC Extra  |  Company News

Valeant eyes hostile takeover of Ista

Valeant Pharmaceuticals International Inc. (NYSE:VRX; TSX:VRX) made public Friday an unsolicited offer to acquire ophthalmic company Ista Pharmaceuticals Inc. (NASDAQ:ISTA) for $6.50 per share in cash, or about $327 million, including Ista's debt. The price...